Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/749
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPreece, Patrick*
dc.contributor.authorYao, Henry H. I.*
dc.contributor.authorChew, Sky*
dc.contributor.authorLiew, Danny*
dc.contributor.authorMcMullin, Richard*
dc.date.accessioned2015-09-25T03:30:58Z-
dc.date.available2015-09-25T03:30:58Z-
dc.date.issued2015en
dc.identifier.govdoc00717en
dc.identifier.urihttp://hdl.handle.net/11054/749-
dc.description.abstractAims: The aim of this article is to compare the effectiveness of PSADT and tPSA as predictors of bony metastases in patients’ with prostate cancer pre-definitive treatment, and help guide clinicians with the selective ordering of bone scans (BS). Materials and methods: PSA measurements were retrospectively analysed for 330 men with prostate cancer, investigated with BS between 2009 and 2012. Exclusion criteria included previous positive BS, other malignancy, prostatectomy/radiotherapy and any prostate-specific condition or treatment initiated between the PSA levels used to calculate doubling time. PSADT (months) = log2 × dT/(log(PSA1)–log(PSA2)). Results: A total of 273 men had negative BS and 57 had positive findings of metastases. Those with positive BS had significantly (p < 0.05) faster median PSADT (4.5 vs 15.2 months) and higher median tPSA (94 vs 24.5 ng/ml). On ROC curve analysis, PSADT outperformed tPSA as a predictor of bone scan result, with area-under-the-curve of 0.85 vs 0.76 (p = 0.02). A ratio (R) of tPSA/PSADT was no better than PSADT alone (p = 0.65). Conclusions: In the absence of clinical reasons to suspect metastatic disease, it is appropriate to withhold ordering a BS for non-prostatectomy/radiotherapy patients with rising PSA levels, until the PSADT is less than 18 months. This has a sensitivity of 100.0% and a specificity of 41.0%.en
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2015-07-23T07:12:45Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2015-09-25T03:30:58Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2015-09-25T03:30:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2015en
dc.publisherBritish Association of Urological Surgeonsen
dc.relation.urihttp://uro.sagepub.com/content/early/2015/04/15/2051415815581097.abstracten
dc.titlePSA doubling time as a screening test to predict bone scan positivity.en
dc.typeJournal Article*
dc.type.specifiedArticleen
dc.bibliographicCitation.titleJournal of Clinical Urologyen
dc.bibliographicCitation.volume2015en
dc.bibliographicCitation.issueApril 15en
dc.bibliographicCitation.stpage1en
dc.bibliographicCitation.endpage6en
dc.publisher.placeLondon, U.K.en
dc.subject.healththesaurusCANCER STAGINGen
dc.subject.healththesaurusMETASTASISen
dc.subject.healththesaurusPROSTATE CANCERen
dc.subject.healththesaurusPROSTATE-SPECIFIC ANTIGENen
dc.subject.healththesaurusPROSTATIC NEOPLASMSen
dc.subject.healththesaurusSCINTIGRAPHYen
dc.date.issuedbrowse2015-01-01en
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.